All of the differences between the groups were statistically significant
Results revealed that clopidogrel plus aspirin was more effective than
The HOST-EXAM Extended study supports clopidogrel
Results revealed that clopidogrel plus aspirin was more effective than
Cost-Effectiveness of Clopidogrel vs Aspirin Monotherapy After Percutaneous
It can potentially alter their effectiveness or increase the risk of side effects
P2Y12 inhibitors include clopidogrel, prasugrel, and ticagrelor: Clopidogrel, the most widely used, has a high level of interpatient variability
1 Aspirin, aspirin in combination with dipyridamole, and clopidogrel alone are currently recommended as first-line agents in secondary prevention of noncardioembolic stroke 1 and reduce the risk of recurrent ischemic events by about
The available evidence demonstrates that the use of clopidogrel plus aspirin in people at high risk of cardiovascular disease and people with established cardiovascular disease without a coronary stent is associated with a reduction in the risk of myocardial infarction and ischaemic stroke, and an increased risk of major and
Based on TEG-PM results there was no significant difference in efficacy of inhibition of platelet activation between aspirin and clopidogrel
01; 95% The observed risk with clopidogrel is significantly lower than that observed with aspirin for GI bleeding (2% versus 2
The cost-effectiveness of both drugs should also be further redefined by using RWE
14, 15, 16 Results from the Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) clinical trial found that compared with aspirin use, clopidogrel was associated with lower risks
1056/NEJM200206063462309
This retrospective cohort study was conducted using the Full Population Data of the Health and Welfare Database in Taiwan
[31,32] The Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events Background: Optimal antiplatelet monotherapy during the chronic maintenance period in patients who undergo coronary stenting is unknown
2010; 160:380
Description and Brand Names
Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event
doi: 10